24/10/2014 14:05:17 Free Membership Login

Xenoport News (NASDAQ:XNPT)

DateTimeSource
Headline
10/23/201410:00AMBWXenoPort to Release Third Quarter Financial Results on November 4
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on November 4, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A... More...>>
09/10/20148:30AMBWXenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829... More...>>
09/09/20148:30AMBWXenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the... More...>>
09/02/201411:00AMBWXenoPort to Present at the Morgan Stanley Global Healthcare Conference
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time) on Tuesday, September 9, 2014. A replay of the presentation will also... More...>>
08/06/20144:05PMBWXenoPort Reports Second Quarter Financial Results
HORIZANT Net Product Sales Increased 66% Over First Quarter 2014 XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2014. Total revenues for the second quarter were $5.3 million, compared to $2.1 million for the same period in 2013. Net loss for the second... More...>>
07/22/201412:00PMBWXenoPort to Release Second Quarter Financial Results on August 6, 2014
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its second quarter financial results on August 6, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. To access... More...>>
06/23/20148:30AMBWXenoPort Announces Initiation of a Phase 2 Clinical Trial of XP23829 in Patients With Psoriasis
XenoPort, Inc. (Nasdaq: XNPT) announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as... More...>>
06/11/20141:06PMBWStockholders Elect ALL Three XenoPort Director Nominees at Annual Meeting
None of Clinton’s Three Nominees Were Elected XenoPort, Inc. (Nasdaq: XNPT) today announced that, based on the estimated vote count provided by its proxy solicitor, stockholders have elected by a wide margin all of the XenoPort director nominees at the Company’s 2014 Annual Meeting of Stockholders: Ronald W. Barrett... More...>>
06/09/201410:00AMBWXenoPort to Present at the 2014 Wells Fargo Healthcare Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Wells Fargo Healthcare Conference. The live presentation will occur at 11:25 a.m. Pacific Time (2:25 p.m. Eastern Time) on Wednesday, June 18, 2014. A replay of the presentation will also be... More...>>
06/06/20148:30AMBWXenoPort Urges Stockholders to Vote "FOR ALL" XenoPort Director Nominees on the WHITE Proxy Card
XenoPort, Inc. (Nasdaq:XNPT) today reminded stockholders to vote at the Company’s upcoming Annual Meeting of Stockholders on June 11, 2014. Time is short and stockholders are encouraged to vote the WHITE proxy card today. XenoPort urges stockholders not to return any proxy card sent to them by Clinton Relational Opportunity... More...>>
06/05/20148:44AMPRNUSCEO Has Special Incentive to Spend on Horizant, Says Clinton Group
CEO Has Special Incentive to Spend on Horizant, Says Clinton Group PR Newswire NEW YORK, June 5, 2014 NEW YORK, June 5, 2014 /PRNewswire/ -- Clinton Group, Inc. ("Clinton Group") announced today that it has sent a letter to the stockholders of XenoPort, Inc. (Nasdaq: XNPT) in advance of the June 11, 2014 XenoPort annual... More...>>
06/03/20148:30AMBWXenoPort Mails Letter to Stockholders Highlighting ISS’s Recommendation That XenoPort Stockholders Vote “FOR ALL” of Xe...
XenoPort, Inc. (Nasdaq: XNPT) today announced that it is mailing a letter to stockholders in connection with the Company's upcoming Annual Meeting, which will be held on June 11, 2014. The letter reviews the May 29, 2014 report issued by Institutional Shareholder Services (ISS), the leading independent proxy advisory... More...>>
06/02/20144:05PMBWSecond Independent Proxy Advisory Firm Recommends that XenoPort Stockholders Vote “FOR ALL” XenoPort Director Nominees on...
Egan-Jones Joins ISS in Supporting XenoPort’s Director Nominees XenoPort, Inc. (Nasdaq: XNPT) today announced that Egan-Jones Proxy Services, an independent proxy advisory firm, has recommended that XenoPort stockholders vote “FOR ALL” of XenoPort’s director nominees on the WHITE proxy card at the Company’s Annual... More...>>
06/02/20149:33AMBWXenoPort to Present New Pooled Data Analyses on HORIZANT (gabapentin enacarbil) at the 2014 SLEEP Annual Meeting
XenoPort, Inc. (Nasdaq:XNPT) announced today that new pooled data analyses for gabapentin enacarbil, the active ingredient of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets, will be presented at the upcoming 28th Associated Professional Sleep Societies (APSS) annual SLEEP meeting in Minneapolis. The presentations... More...>>
05/30/20148:30AMBWLeading Independent Proxy Advisory Firm ISS Recommends XenoPort Stockholders Vote FOR ALL XenoPort Director Nominees
Recommends Stockholders “Do Not Vote” For Any of the Clinton Nominees XenoPort, Inc. (Nasdaq: XNPT) today announced that Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that XenoPort stockholders vote “FOR ALL” of XenoPort’s director nominees on the WHITE proxy... More...>>
05/27/201410:00AMBWXenoPort to Present at the Jefferies 2014 Global Healthcare Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Jefferies 2014 Global Healthcare Conference. The live presentation will occur at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Wednesday, June 4, 2014. A replay of the presentation will also... More...>>
05/22/201412:32PMPRNUSXenoPort Board Ignores Key Issue, Says Clinton Group
XenoPort Board Ignores Key Issue, Says Clinton Group PR Newswire NEW YORK, May 22, 2014 NEW YORK, May 22, 2014 /PRNewswire/ -- Clinton Group, Inc. ("Clinton Group") announced today that it has sent a letter to the stockholders of XenoPort, Inc. (Nasdaq: XNPT) in advance of the June 11, 2014 XenoPort annual meeting. The... More...>>
05/21/201410:05AMBWXenoPort Files Investor Presentation
XenoPort Has the Right Strategy and Board to Build Stockholder Value Highlights Progress Company is Making Executing its Strategy to Realize Full Value of XenoPort’s Assets Board Urges XenoPort Stockholders to Vote “FOR ALL” XenoPort Director Nominees on WHITE Card Today XenoPort, Inc. (Nasdaq: XNPT) today announced... More...>>
05/15/20149:08AMDJNCorrection to XenoPort Story
"XenoPort Reaches Licensing Deal With Reckitt Benckiser" published at 8:21 a.m. EDT incorrectly said XenoPort is planning a Phase IIB study of arbaclofen placarbil. Reckitt Benckiser is planning the study. Subscribe to WSJ: http://online.wsj.com?mod=djnwires More...>>
05/15/20149:05AMDJNXenoPort Reaches Licensing Deal With Reckitt Benckiser --Update
By Tess Stynes XenoPort Inc. (XNPT) agreed to a licensing deal that grants exclusive worldwide rights to develop the company's product candidate to treat alcohol-use disorders to Reckitt Benckiser Group PLC (RBGLY,RB.LN). The deal has a potential value of as much as $145 million for the biopharmaceutical company, which... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xnpt141024 14:05